A comparative analysis of vaccine lists, prices, and candidates, and the national immunization program between China and the United States

Vaccines have an essential role in preventing infectious diseases and reducing the burden of disease. The differences in vaccine lists and prices, and the National Immunization Program (NIP) and vaccine development between China and the United States (US) in conjunction with epidemiologic data on infectious diseases were systematically compared. The epidemiologic data of infectious diseases in 2019 were extracted from the China National Health Commission and the US Centers for Disease Control and Prevention (CDC). The vaccine list was identified from the China National Medical Products Administration and US Food and Drug Administration databases. Vaccine prices were obtained via the China government procurement platform and the US CDC. The NIP vaccines for China and the US were obtained from the China and US CDCs. Vaccine candidates investigated in 2015-2022 were identified from the China Clinical Trial Registry Platform and the US clinicaltrials.gov database. Differences in the incidence of infectious diseases between China and the US were detected with both countries facing a lack of available vaccines for prevention of many diseases. The number of listed vaccines and preventable diseases in China was 59 and 36, respectively, which was higher than the US (45 and 31, respectively). The median price of NIP vaccines in China was significantly lower than the price in the US (median: $3.8 vs. $20; P<0.001); however, there was no significant difference in the price of non-NIP vaccines (median: $68 vs. $86; P=0.498). Vaccines developed by local manufacturers were less expensive than imported products despite the absence of significant differences (median: $16 vs. $31; P=0.180). The number and types of NIP vaccines used to prevent infectious diseases in China were lower than the US. The majority of vaccine candidates in China were not novel compared to the US. Vaccines marketed in China for infectious diseases were comparable to the US. Our findings suggest that China should further expand NIP vaccines and incentive research and development on novel vaccines to improve accessibility based on infectious disease epidemiology.

[1]  S. Chow,et al.  The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis , 2022, The Lancet regional health. Western Pacific.

[2]  Xingxian Luo,et al.  Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021 , 2022, Clinical pharmacology and therapeutics.

[3]  Yanrong Li,et al.  Assessment of the breakthrough-therapy-designated drugs granted in China: a pooled analysis 2020-2022. , 2022, Drug discovery today.

[4]  Xingxian Luo,et al.  Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021 , 2022, Clinical pharmacology and therapeutics.

[5]  W. Yin,et al.  Dengue Fever in Mainland China, 2005–2020: A Descriptive Analysis of Dengue Cases and Aedes Data , 2022, International journal of environmental research and public health.

[6]  K. Poehling,et al.  Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021 , 2021, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[7]  A. Usher.  Vaccine shortages prompt changes to COVAX strategy , 2021, The Lancet.

[8]  J. Tregoning,et al.  Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.

[9]  A. Yılmaz,et al.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.

[10]  H. Wedemeyer,et al.  Hepatitis E: An update on One Health and clinical medicine , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[11]  Ling-sheng Cao,et al.  Impact of immunization programs on 11 childhood vaccine-preventable diseases in China: 1950–2018 , 2021, Innovation.

[12]  Lesly A. Dossett,et al.  HPV Vaccination Among Young Adults in the US. , 2021, JAMA.

[13]  Jerome H. Kim,et al.  Vaccine development for emerging infectious diseases , 2021, Nature Medicine.

[14]  Hannah Ritchie,et al.  A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.

[15]  J. Gerberding,et al.  Vaccine Innovations - Past and Future. , 2021, New England Journal of Medicine.

[16]  A. Pollard,et al.  A guide to vaccinology: from basic principles to new developments , 2020, Nature reviews. Immunology.

[17]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[18]  M. Postma,et al.  Health Economics of Vaccines: From Current Practice to Future Perspectives , 2020, Value in Health.

[19]  J. Hocking,et al.  Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. , 2020, The Lancet. Global health.

[20]  Yanqun Liu,et al.  Human papillomavirus vaccination: coverage rate, knowledge, acceptance, and associated factors in college students in mainland China , 2020, Human vaccines & immunotherapeutics.

[21]  Health , 2020, Arab Society: A Compendium of Social Statistics.

[22]  A. Clements,et al.  A cost analysis of producing vaccines in developing countries. , 2019, Vaccine.

[23]  R. Scherpbier,et al.  Vaccine-preventable disease control in the People’s Republic of China: 1949–2016 , 2018, Vaccine.

[24]  Juan Yang,et al.  The landscape of vaccines in China: history, classification, supply, and price , 2018, BMC Infectious Diseases.

[25]  M. Maiden,et al.  Invasive meningococcal disease in Shanghai, China from 1950 to 2016: implications for serogroup B vaccine implementation , 2018, Scientific Reports.

[26]  M. Jit,et al.  The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries. , 2018, Health affairs.

[27]  J. Absalon,et al.  A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults , 2017, The New England journal of medicine.

[28]  J. Cuzick,et al.  Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial , 2017, The Lancet.

[29]  Wei Chen,et al.  Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial , 2017, The Lancet.

[30]  W. J. Ramsey,et al.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine , 2017, The New England journal of medicine.

[31]  Ruoran Li,et al.  Human papillomavirus vaccine approval in China: a major step forward but challenges ahead. , 2016, The Lancet. Infectious diseases.

[32]  C. Bauch,et al.  National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States , 2016, Proceedings of the National Academy of Sciences.

[33]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[34]  J. Luyten,et al.  The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness. , 2016, Health affairs.

[35]  Junzhi Wang,et al.  Chinese vaccine products go global: vaccine development and quality control , 2015, Expert review of vaccines.

[36]  D. Grobbee,et al.  Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. , 2015, The New England journal of medicine.

[37]  N. Xia,et al.  Long-term efficacy of a hepatitis E vaccine. , 2015, The New England journal of medicine.

[38]  L. Kamara,et al.  World Health Organization perspectives on the contribution of the Global Alliance for Vaccines and Immunization on reducing child mortality , 2015, Archives of Disease in Childhood.

[39]  M. Gautam,et al.  Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[40]  A. Schuchat,et al.  Benefits from Immunization During the Vaccines for Children Program Era — United States, 1994–2013 , 2014, MMWR. Morbidity and mortality weekly report.

[41]  Wenbo Xu,et al.  Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. , 2014, The New England journal of medicine.

[42]  A. Pollard,et al.  Meningococcal disease: clinical presentation and sequelae. , 2012, Vaccine.

[43]  Jane J. Kim.  The role of cost-effectiveness in U.S. vaccination policy. , 2011, The New England journal of medicine.

[44]  N. Xia,et al.  Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial , 2010, The Lancet.

[45]  Xiaofeng Liang,et al.  Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial , 2010, The Lancet.

[46]  R. Vignon.  HEALTH ORGANIZATION , 1925, Techniques hospitalieres, medico-sociales et sanitaires.